Mitochondrial dysfunction in epilepsy and autism
Investigating high-frequency oscillations as a biomarker of the mitochondrial dysfunction linked to epilepsy in autism.
People with autism spectrum disorder (ASD) are at increased risk of epilepsy, and the risk of new-onset seizures keeps rising into adolescence and young adulthood. Epilepsy in people with ASD is harder to treat, and it is the leading cause of death in young adults with ASD.
We need better biomarkers of epilepsy risk in ASD, to predict who needs treatment or monitoring. We also need a better understanding of the biological mechanisms that underlie epilepsy, so that we can develop new and effective therapies.
About this project
Mitochondrial dysfunction has been linked to epilepsy, but biomarkers of mitochondrial dysfunction in the brain are still largely limited to research methods. Our laboratory can measure mitochondrial function in fresh human brain tissue removed during surgery to take out the areas that cause epilepsy.
We have correlated mitochondrial dysfunction in this tissue with high-frequency oscillations (HFOs) in electrophysiological recordings of brain activity made before surgery, during the epilepsy evaluation. This project will study mitochondrial dysfunction as a cause of epilepsy in people with and without ASD. It will also study how these areas of mitochondrial dysfunction correlate with HFOs that can be recorded non-invasively, as a biomarker of mitochondria-associated epilepsy.
The work aims to improve the identification of epilepsy in people with ASD, and of mitochondrial dysfunction in the brain, so that effective targeted treatments can be given to control seizures.
Principal investigator: Richard E. Frye
Funded by: The BRAIN Foundation and the O’Sullivan Foundation
Bioenergetic signatures of neurodevelopmental regression
Mitochondrial dysfunction associated with regression: further development of in vitro models and pathways to treatment.
About one-third of children with ASD go through a major neurodevelopmental regression (NDR). They lose skills, most often language and social interaction, and develop restricted and repetitive behaviors that lead to the diagnosis of ASD.
About this project
Over the past ten years we have developed a cellular model of ASD. In it, the mitochondria, the powerhouses of our cells, show a unique type of dysfunction that is quantitatively different from classically defined mitochondrial disease. The model reproduces the clinical picture, in which an environmental trigger (such as a toxicant, inflammation or infection) results in NDR. We have also found that children with ASD and NDR may have a distinct mitochondrial signature.
This project aims to develop the model and this mitochondrial biomarker of NDR further, and to discover new targeted treatments for this subgroup of children with ASD.
Principal investigator: Richard E. Frye
Funded by: The BRAIN Foundation and the O’Sullivan Foundation
Understanding transgenerational folate abnormalities
In children with ASD and their families.
Our group has found that a substantial subgroup of people with ASD have abnormal folate metabolism that prevents folate from being transported into the brain. The main cause is folate receptor alpha autoantibodies (FRAAs) in the blood, which stop the folate receptor alpha from carrying folate across the blood–brain barrier.
Our previous clinical trials have shown that leucovorin, a special form of folate that bypasses this block, is safe, effective and well tolerated, and improves core and associated symptoms. Because this treatment may address the underlying pathophysiology driving ASD, it could have disease-modifying potential.
About this project
This project builds on our ongoing research. It aims to:
- Investigate how FRAAs and associated metabolic abnormalities are inherited, to better understand transgenerational folate pathway and metabolic abnormalities in ASD. We will study family members (the child with ASD, mother, father and siblings) and control families without children with ASD.
- Study changes in methylation in the nuclear and mitochondrial genome, and their association with folate pathway abnormalities and mitochondrial function, in families with and without children with ASD.
- Develop alternative methods for measuring FRAAs, and identify the soluble folate receptor or binding protein(s) so that an assay to measure them can be developed.
- Continue our work to develop new assessment instruments, and validate existing ones, for minimally verbal individuals, so that they can be studied in clinical trials and treatments can be developed for them.
Principal investigator: Richard E. Frye
Funded by: The XEL Foundation, Pittsburgh, PA
Metabolic treatments
Targeting abnormal physiological processes underlying ASD.
We are developing medical treatments that target the abnormal physiological processes underlying ASD, to correct disturbances that may be causing it. To do this, we are investigating metabolic pathways.
About this project
Many metabolic pathways are known to be abnormal in ASD. Metabolism is very complex, so these disruptions must be studied carefully to identify the key pathway or pathways to target. An advantage of working on metabolism is that it may be correctable with non-toxic treatments, including diet and vitamins.
We have already carried out several studies showing the benefits of correcting metabolic pathways. More studies are needed to understand these pathways better, develop biomarkers and optimize targeted treatments.
Principal investigator: Richard E. Frye
Funded by: Donations to the foundation
Leucovorin
Studying whether folate treatment can prevent ASD.
Careful research and clinical observation led us to discover that folate abnormalities may play a role in causing ASD. Further work led to biomarkers for these folate abnormalities and a potentially effective treatment.
About this project
The treatment is a special form of folate that bypasses blocks in folate metabolism associated with ASD. These findings have been preliminarily validated. More research is needed to develop the treatment further for children with ASD, and to find out whether it can prevent ASD if it is given before symptoms appear.
Principal investigator: Richard E. Frye
Funded by: Donations to the foundation
The C.O.M.P.R.E.H.E.N.S.I.V.E. project
Complete Onboarding: Medical Conditions, Prenatal Risks, Environment, History, Evaluations, Neurodevelopmental Milestones, Symptoms, Interventions, Variables, and Education.
We are creating a comprehensive way to gather and analyze patient data, to help diagnose ASD and other neurodevelopmental conditions and to track treatment outcomes over time.
About this project
The project has four goals:
- Make it easy for parents and guardians to supply the patient information needed.
- Give clinicians thorough reports, so they can analyze a patient’s situation quickly and in depth.
- Standardize how data are collected.
- Produce longitudinal results that track outcomes over time.
We believe this tool will help clinicians diagnose and treat ASD and other neurodevelopmental disorders.
Timeline: The project is expected to roll out in four stages, one per quarter in 2024.
Cost: The project’s costs include technology development, infrastructure and data security.